These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34931694)

  • 1. Does canagliflozin decrease natriuretic peptide levels in patients with diabetes and heart failure?
    Martín E; Castillo JC; González-Manzanares R; López Aguilera J; Perea J; Anguita M
    Cardiol J; 2022; 29(1):166-169. PubMed ID: 34931694
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
    Sezai A; Sekino H; Unosawa S; Taoka M; Osaka S; Tanaka M
    Cardiovasc Diabetol; 2019 Jun; 18(1):76. PubMed ID: 31167663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
    Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
    Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B
    Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240
    [No Abstract]   [Full Text] [Related]  

  • 6. Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
    Sharma A; Marques P; Neuen BL; Fletcher RA; Slee A; Rapattoni W; Ang FG; Arnott C; Levin A; Verma S; Perkovic V; Mahaffey KW
    Diabetes Obes Metab; 2024 Feb; 26(2):758-762. PubMed ID: 37881140
    [No Abstract]   [Full Text] [Related]  

  • 7. Limitations of Natriuretic Peptide Levels in Establishing SGLT-2 Inhibitors for Heart Failure Care.
    Velazquez EJ; Reinhardt SW
    J Am Coll Cardiol; 2020 Nov; 76(18):2086-2088. PubMed ID: 33121715
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.
    Tanaka A; Imai T; Shimabukuro M; Nakamura I; Matsunaga K; Ozaki Y; Minamino T; Sata M; Node K;
    J Diabetes Investig; 2022 Dec; 13(12):1990-1999. PubMed ID: 36114704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
    Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
    J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial.
    Yamaguchi S; Shimabukuro M; Tanaka A; Imai T; Hiramitsu S; Takahashi N; Kadokami T; Ajioka M; Suzuki M; Node K;
    Diabetes Obes Metab; 2023 Feb; 25(2):354-364. PubMed ID: 36193841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
    Januzzi JL; Butler J; Jarolim P; Sattar N; Vijapurkar U; Desai M; Davies MJ
    J Am Coll Cardiol; 2017 Aug; 70(6):704-712. PubMed ID: 28619659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.
    Kario K; Hoshide S; Okawara Y; Tomitani N; Yamauchi K; Ohbayashi H; Itabashi N; Matsumoto Y; Kanegae H
    J Clin Hypertens (Greenwich); 2018 Oct; 20(10):1527-1535. PubMed ID: 30246286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.
    Li J; Woodward M; Perkovic V; Figtree GA; Heerspink HJL; Mahaffey KW; de Zeeuw D; Vercruysse F; Shaw W; Matthews DR; Neal B
    JACC Heart Fail; 2020 Jan; 8(1):57-66. PubMed ID: 31676303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Vaduganathan M; Januzzi JL
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
    Vaduganathan M; Sattar N; Xu J; Butler J; Mahaffey KW; Neal B; Shaw W; Rosenthal N; Pfeifer M; Hansen MK; Januzzi JL
    J Am Coll Cardiol; 2022 Feb; 79(5):432-444. PubMed ID: 35115099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis.
    Khan MS; Usman MS; Siddiqi TJ; Memon MM; Shah SJ; Khan SS
    Eur J Prev Cardiol; 2019 Oct; 26(15):1680-1682. PubMed ID: 30755019
    [No Abstract]   [Full Text] [Related]  

  • 17. Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication.
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2020 Jan; 12(1):8-9. PubMed ID: 31722441
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
    Sarraju A; Li J; Cannon CP; Chang TI; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey KW
    Am Heart J; 2021 Mar; 233():141-148. PubMed ID: 33358942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
    Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M
    Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.